Youth Overdose & Use Reduction in Rural Systems (YOURS)
YOURS Study: Youth Overdose & Use Reduction in Rural Systems
The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.
The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.
The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.
Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.
Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.
Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.
Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Youth age 14-18
- Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
- Received a REDCap link or QR code and study participation code from authorized county staff
Exclusion Criteria:
- Youth age 13 and under
- Youth who do not receive a study participation code from an authorized county contact
- Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention: YOURS Navigator Program
The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties. |
Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.
Other Names:
|
|
No Intervention: Usual Care
No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overdose Prevention Knowledge
Time Frame: 3- and 6-months
|
Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome. |
3- and 6-months
|
|
Presence of use past 30 days (Yes/No)
Time Frame: 3- and 6-months
|
Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days |
3- and 6-months
|
|
Number of days using alcohol and cannabis
Time Frame: 3- and 6-months
|
In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol. |
3- and 6-months
|
|
Number of youth receiving case management, mental health, or substance use prevention services
Time Frame: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of naloxone kits distributed
Time Frame: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of days of using other individual non-alcohol/non-cannabis substances
Time Frame: 3- and 6- months
|
Measure taken from the HEAL Prevention Cooperative Common Core Measures |
3- and 6- months
|
|
Substance use refusal self-efficacy
Time Frame: 3- and 6-months
|
How confident youth are resisting substances. |
3- and 6-months
|
|
Percent of youth reporting receipt of naloxone
Time Frame: 3 months
|
Percent of youth receiving naloxone, a medication to reverse an opioid overdose. |
3 months
|
|
Number of youth receiving overdose prevention education
Time Frame: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of court staff receiving overdose prevention education
Time Frame: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of non-fatal overdose
Time Frame: 3- and 6-months
|
Exploratory outcome, investigator-developed |
3- and 6-months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-007-SCH
- R61DA061846 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).
IPD Sharing Time Frame
IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).
IPD Sharing Access Criteria
Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.